Anika Therapeutics (ANIK) EBT (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of EBT data on file, last reported at -$4.8 million in Q1 2026.

• On a quarterly basis, EBT fell 24.61% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$10.3 million, a 70.02% decrease from a year earlier, with the FY2025 full-year figure at -$9.3 million, down 128.22% from the prior year.
• EBT for Q1 2026 stood at -$4.8 million, down from $764000.0 in the prior quarter.
• Over the last five years, EBT for ANIK reached as high as $24.5 million in Q4 2023 and fell as low as -$12.0 million in Q1 2023.
• Historically, EBT has averaged -$674176.5 across 5 years, with a median of -$3.1 million in 2023.
• Across the five-year window, EBT jumped 218.07% in 2022 and plunged 788.0% in 2025, its largest moves.
• Year by year, EBT stood at $16.7 million in 2022, then surged by 47.16% to $24.5 million in 2023, then sank by 105.19% to -$1.3 million in 2024, then soared by 159.92% to $764000.0 in 2025, then slumped by 731.02% to -$4.8 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$4.8 million in Q1 2026, $764000.0 in Q4 2025, and -$2.2 million in Q3 2025.